aspartic acid has been researched along with Depressive Disorder, Major in 77 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| " MDD patients had significantly higher serum levels of glutamic acid, aspartic acid and glycine but lower levels of 3-Hydroxykynurenine; glutamic acid and phenylalanine levels also correlated with depression severity." | 4.31 | The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity. ( Ching, J; Ho, CSH; Tay, GWN; Wee, HN, 2023) |
| "Symptoms of GAD overlap with those of major depressive disorder to such an extent that studying one disorder without studying the other may be impossible." | 2.45 | Neurobiology of generalized anxiety disorder. ( Stein, MB, 2009) |
| "Previous studies have shown major depressive disorder (MDD) is associated with altered neuro-metabolites in the anterior cingulate cortex (ACC)." | 1.72 | Regional metabolic heterogeneity in anterior cingulate cortex in major depressive disorder: A multi-voxel ( Ban, M; He, J; Kong, L; Wang, D; Xiao, Q; Yuan, F; Zhu, X, 2022) |
| "Ketamine is an anesthetic with antidepressant properties." | 1.42 | The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015) |
| "Smaller hippocampal volumes in major depressive disorder (MDD) have been linked with earlier onset, previous recurrences and treatment refractoriness." | 1.39 | Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden. ( Álvarez, E; de Diego-Adeliño, J; Gómez-Ansón, B; López-Moruelo, O; Pérez, V; Pérez-Egea, R; Portella, MJ; Puigdemont, D; Serra-Blasco, M; Vives, Y, 2013) |
| "Seventy-five elderly patients with major depressive disorder in remission underwent assessment of insight using the Mood Disorders Insight Scale (MDIS), including awareness, attribution, and need for treatment." | 1.36 | Brain proton magnetic resonance spectroscopic study of insight among elders with late-life depression in remission. ( Chang, HC; Chen, CS; Ko, CH; Kuo, YT; Li, CW; Lin, HF; Liu, GC; Yeh, YC; Yen, CF, 2010) |
| "Patients with late-life major depressive disorder had a significantly lower NAA/creatine ratio in the left frontal white matter, and higher Cho/creatine and myo-inositol/creatine ratios in the left basal ganglia when compared with the control subjects." | 1.35 | Proton magnetic resonance spectroscopy of late-life major depressive disorder. ( Chen, CS; Chiang, IC; Hsieh, TJ; Kuo, YT; Li, CW; Lin, HF; Lin, WC; Liu, GC; Lu, CY, 2009) |
| "The neural underpinnings of major depressive disorder (MDD) are unknown but there is evidence for structural alteration in the hippocampus that may become more pronounced over the course of illness." | 1.35 | Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study. ( Hall, GB; MacQueen, GM; Milne, A; Soreni, N; Yucel, K, 2009) |
| "Co-morbidities of PTSD, notably alcohol abuse, may have contributed to the inconsistency." | 1.35 | Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder. ( Fox-Bosetti, S; Kornak, J; Lenoci, M; Marmar, CR; Neylan, TC; Samuelson, KW; Schuff, N; Studholme, C; Weiner, MW, 2008) |
| "Patients with type 2 diabetes and major depression (n=20) were scanned along with patients with diabetes alone (n=24) and healthy controls (n=21) on a 1." | 1.34 | Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy. ( Ajilore, O; Binesh, N; Darwin, C; Haroon, E; Kumar, A; Kumaran, S; Miller, J; Mintz, J; Thomas, MA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.30) | 18.2507 |
| 2000's | 30 (38.96) | 29.6817 |
| 2010's | 35 (45.45) | 24.3611 |
| 2020's | 11 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Lv, S | 2 |
| Zhong, S | 7 |
| Zhang, S | 1 |
| Lai, S | 5 |
| Wang, Y | 9 |
| Zhao, H | 3 |
| Zhang, Y | 3 |
| Luo, Y | 2 |
| Yan, S | 2 |
| Ran, H | 2 |
| Chen, P | 4 |
| Chen, G | 4 |
| Jia, Y | 9 |
| Wu, W | 1 |
| He, J | 3 |
| Zhu, Y | 2 |
| Qi, Z | 1 |
| Song, Z | 2 |
| Hu, Y | 1 |
| Miao, H | 2 |
| Huang, X | 2 |
| Lu, X | 2 |
| Liu, X | 1 |
| Chabert, J | 1 |
| Allauze, E | 1 |
| Pereira, B | 1 |
| Chassain, C | 1 |
| De Chazeron, I | 1 |
| Rotgé, JY | 1 |
| Fossati, P | 1 |
| Llorca, PM | 1 |
| Samalin, L | 1 |
| Wang, D | 1 |
| Ban, M | 1 |
| Kong, L | 1 |
| Xiao, Q | 1 |
| Yuan, F | 1 |
| Zhu, X | 1 |
| Ye, K | 1 |
| Duan, M | 1 |
| Song, K | 1 |
| Ho, CSH | 1 |
| Tay, GWN | 1 |
| Wee, HN | 1 |
| Ching, J | 1 |
| Pavlova, I | 1 |
| Ruda-Kucerova, J | 1 |
| Güleş, E | 1 |
| Iosifescu, DV | 1 |
| Tural, Ü | 1 |
| Kahl, KG | 1 |
| Atalay, S | 1 |
| Maudsley, AA | 1 |
| Sheriff, S | 1 |
| Cummings, A | 1 |
| Frieling, H | 1 |
| Schmitz, B | 1 |
| Lanfermann, H | 1 |
| Ding, XQ | 1 |
| Smith, GS | 1 |
| Oeltzschner, G | 1 |
| Gould, NF | 1 |
| Leoutsakos, JS | 1 |
| Nassery, N | 1 |
| Joo, JH | 1 |
| Kraut, MA | 1 |
| Edden, RAE | 1 |
| Barker, PB | 2 |
| Wijtenburg, SA | 1 |
| Rowland, LM | 1 |
| Workman, CI | 1 |
| Freed, RD | 1 |
| Hollenhorst, CN | 1 |
| Weiduschat, N | 1 |
| Mao, X | 2 |
| Kang, G | 2 |
| Shungu, DC | 2 |
| Gabbay, V | 3 |
| Shan, Y | 1 |
| Li, X | 1 |
| Chen, J | 1 |
| Lu, Q | 1 |
| Zhang, L | 1 |
| Li, Z | 1 |
| Knudsen, MK | 1 |
| Near, J | 3 |
| Blicher, AB | 1 |
| Videbech, P | 1 |
| Blicher, JU | 1 |
| Moriguchi, S | 1 |
| Takamiya, A | 1 |
| Noda, Y | 1 |
| Horita, N | 1 |
| Wada, M | 1 |
| Tsugawa, S | 1 |
| Plitman, E | 1 |
| Sano, Y | 1 |
| Tarumi, R | 1 |
| ElSalhy, M | 1 |
| Katayama, N | 1 |
| Ogyu, K | 1 |
| Miyazaki, T | 1 |
| Kishimoto, T | 1 |
| Graff-Guerrero, A | 1 |
| Meyer, JH | 1 |
| Blumberger, DM | 1 |
| Daskalakis, ZJ | 1 |
| Mimura, M | 1 |
| Nakajima, S | 1 |
| Bansal, R | 1 |
| Hellerstein, DJ | 1 |
| Sawardekar, S | 1 |
| O'Neill, J | 1 |
| Peterson, BS | 1 |
| de Diego-Adeliño, J | 2 |
| Portella, MJ | 2 |
| Gómez-Ansón, B | 2 |
| López-Moruelo, O | 1 |
| Serra-Blasco, M | 1 |
| Vives, Y | 2 |
| Puigdemont, D | 2 |
| Pérez-Egea, R | 2 |
| Álvarez, E | 1 |
| Pérez, V | 2 |
| Tae, WS | 1 |
| Kim, SS | 1 |
| Lee, KU | 1 |
| Nam, EC | 1 |
| Koh, SH | 1 |
| Chen, LP | 1 |
| Dai, HY | 1 |
| Dai, ZZ | 1 |
| Xu, CT | 2 |
| Wu, RH | 2 |
| Lu, YR | 2 |
| Fu, XY | 2 |
| Shi, LG | 1 |
| Jiang, Y | 1 |
| Wu, JL | 2 |
| Weng, XJ | 1 |
| Wang, ZP | 1 |
| Wu, XY | 2 |
| Lin, Z | 1 |
| Liu, WB | 1 |
| Li, HC | 1 |
| Luo, JH | 1 |
| Bao, AM | 2 |
| Yang, D | 1 |
| Yang, Y | 1 |
| Li, J | 1 |
| Cheng, K | 1 |
| Tang, G | 1 |
| Zhang, R | 1 |
| Zhou, J | 1 |
| Li, W | 1 |
| Liu, Z | 1 |
| Fan, S | 1 |
| Xie, P | 1 |
| Zhao, G | 1 |
| Xiang, Q | 1 |
| Ling, X | 3 |
| Liu, S | 4 |
| Huang, L | 4 |
| Liu, T | 1 |
| Liao, X | 1 |
| Melo, A | 1 |
| Kokras, N | 1 |
| Dalla, C | 1 |
| Ferreira, C | 1 |
| Ventura-Silva, AP | 1 |
| Sousa, N | 1 |
| Pêgo, JM | 1 |
| Bradley, KA | 1 |
| Case, JA | 1 |
| Yoon, S | 1 |
| Kim, JE | 1 |
| Hwang, J | 1 |
| Kim, TS | 1 |
| Kang, HJ | 1 |
| Namgung, E | 1 |
| Ban, S | 1 |
| Oh, S | 1 |
| Yang, J | 1 |
| Renshaw, PF | 1 |
| Lyoo, IK | 1 |
| Li, Y | 1 |
| Jakary, A | 1 |
| Gillung, E | 1 |
| Eisendrath, S | 1 |
| Nelson, SJ | 1 |
| Mukherjee, P | 1 |
| Luks, T | 1 |
| Ernst, J | 1 |
| Hock, A | 1 |
| Henning, A | 2 |
| Seifritz, E | 1 |
| Boeker, H | 2 |
| Grimm, S | 3 |
| Jollant, F | 1 |
| Richard-Devantoy, S | 1 |
| Ding, Y | 1 |
| Turecki, G | 1 |
| Bechara, A | 1 |
| Lefebvre, D | 1 |
| Langevin, LM | 1 |
| Jaworska, N | 1 |
| Harris, AD | 1 |
| Lebel, RM | 1 |
| Jasaui, Y | 1 |
| Kirton, A | 1 |
| Wilkes, TC | 1 |
| Sembo, M | 1 |
| Swansburg, R | 1 |
| MacMaster, FP | 3 |
| Tan, HZ | 1 |
| Li, H | 1 |
| Liu, CF | 1 |
| Guan, JT | 1 |
| Guo, XB | 1 |
| Wen, CH | 1 |
| Ou, SM | 1 |
| Zhang, YN | 1 |
| Zhang, J | 2 |
| Shen, ZW | 1 |
| Wang, XQ | 1 |
| Moore, GJ | 2 |
| Russell, A | 2 |
| Mirza, Y | 2 |
| Taormina, SP | 1 |
| Buhagiar, C | 1 |
| Rosenberg, DR | 2 |
| Block, W | 1 |
| Träber, F | 1 |
| von Widdern, O | 1 |
| Metten, M | 1 |
| Schild, H | 1 |
| Maier, W | 2 |
| Zobel, A | 1 |
| Jessen, F | 1 |
| Venkatraman, TN | 1 |
| Krishnan, RR | 1 |
| Steffens, DC | 1 |
| Song, AW | 1 |
| Taylor, WD | 1 |
| Chen, CS | 2 |
| Chiang, IC | 1 |
| Li, CW | 2 |
| Lin, WC | 1 |
| Lu, CY | 1 |
| Hsieh, TJ | 1 |
| Liu, GC | 2 |
| Lin, HF | 2 |
| Kuo, YT | 2 |
| Milne, A | 1 |
| MacQueen, GM | 1 |
| Yucel, K | 1 |
| Soreni, N | 1 |
| Hall, GB | 1 |
| Stein, MB | 1 |
| Walter, M | 1 |
| Schulte, RF | 1 |
| Beck, J | 1 |
| Dydak, U | 1 |
| Schnepf, B | 1 |
| Boesiger, P | 1 |
| Northoff, G | 1 |
| Kaymak, SU | 1 |
| Demir, B | 1 |
| Oğuz, KK | 1 |
| Sentürk, S | 1 |
| Uluğ, B | 1 |
| Nery, FG | 1 |
| Stanley, JA | 2 |
| Chen, HH | 2 |
| Hatch, JP | 2 |
| Nicoletti, MA | 1 |
| Monkul, ES | 1 |
| Matsuo, K | 1 |
| Caetano, SC | 2 |
| Peluso, MA | 1 |
| Najt, P | 1 |
| Soares, JC | 2 |
| Rao, V | 1 |
| Munro, CA | 1 |
| Rosenberg, P | 1 |
| Ward, J | 1 |
| Bertrand, M | 1 |
| Degoankar, M | 1 |
| Horská, A | 1 |
| Pham, D | 1 |
| Yousem, DM | 1 |
| Ko, CH | 1 |
| Yeh, YC | 1 |
| Chang, HC | 1 |
| Yen, CF | 1 |
| Reynolds, LM | 1 |
| Reynolds, GP | 1 |
| Olvera, RL | 1 |
| Nicoletti, M | 1 |
| Fonseca, M | 1 |
| Pliszka, SR | 1 |
| Morgan-Ferrando, R | 1 |
| Ruscalleda, J | 1 |
| Merkl, A | 1 |
| Schubert, F | 1 |
| Quante, A | 1 |
| Luborzewski, A | 1 |
| Brakemeier, EL | 1 |
| Heuser, I | 1 |
| Bajbouj, M | 1 |
| Kohli, MA | 1 |
| Lucae, S | 1 |
| Saemann, PG | 1 |
| Schmidt, MV | 1 |
| Demirkan, A | 1 |
| Hek, K | 1 |
| Czamara, D | 1 |
| Alexander, M | 1 |
| Salyakina, D | 1 |
| Ripke, S | 1 |
| Hoehn, D | 1 |
| Specht, M | 1 |
| Menke, A | 1 |
| Hennings, J | 1 |
| Heck, A | 1 |
| Wolf, C | 1 |
| Ising, M | 1 |
| Schreiber, S | 1 |
| Czisch, M | 2 |
| Müller, MB | 1 |
| Uhr, M | 1 |
| Bettecken, T | 1 |
| Becker, A | 1 |
| Schramm, J | 1 |
| Rietschel, M | 1 |
| Bradley, B | 1 |
| Ressler, KJ | 1 |
| Nöthen, MM | 1 |
| Cichon, S | 1 |
| Craig, IW | 1 |
| Breen, G | 1 |
| Lewis, CM | 1 |
| Hofman, A | 1 |
| Tiemeier, H | 1 |
| van Duijn, CM | 1 |
| Holsboer, F | 3 |
| Müller-Myhsok, B | 1 |
| Binder, EB | 1 |
| Xu, G | 2 |
| Knapman, A | 1 |
| Kaltwasser, SF | 1 |
| Martins-de-Souza, D | 1 |
| Landgraf, R | 1 |
| Turck, CW | 1 |
| Touma, C | 1 |
| Taylor, MJ | 1 |
| Godlewska, BR | 1 |
| Norbury, R | 1 |
| Selvaraj, S | 1 |
| Cowen, PJ | 1 |
| Narr, KL | 1 |
| Woods, RP | 1 |
| Phillips, OR | 1 |
| Alger, JR | 1 |
| Espinoza, RT | 1 |
| Chen, X | 1 |
| Salehi, B | 1 |
| Preuss, N | 1 |
| van der Veen, JW | 1 |
| Shen, J | 1 |
| Neumeister, A | 1 |
| Drevets, WC | 1 |
| Hodgkinson, C | 1 |
| Goldman, D | 1 |
| Wendland, JR | 1 |
| Singleton, A | 1 |
| Gibbs, JR | 1 |
| Cookson, MR | 1 |
| Hasler, G | 1 |
| Das, P | 1 |
| Tanious, M | 1 |
| Fritz, K | 1 |
| Dodd, S | 1 |
| Dean, OM | 1 |
| Berk, M | 1 |
| Malhi, GS | 1 |
| Michael, N | 1 |
| Erfurth, A | 1 |
| Ohrmann, P | 1 |
| Arolt, V | 1 |
| Heindel, W | 1 |
| Pfleiderer, B | 1 |
| Obergriesser, T | 1 |
| Ende, G | 2 |
| Braus, DF | 1 |
| Henn, FA | 2 |
| Vythilingam, M | 1 |
| Charles, HC | 1 |
| Tupler, LA | 1 |
| Blitchington, T | 1 |
| Kelly, L | 1 |
| Krishnan, KR | 1 |
| Paul, IA | 1 |
| Skolnick, P | 1 |
| Wood, SJ | 1 |
| Berger, G | 1 |
| Velakoulis, D | 1 |
| Phillips, LJ | 1 |
| McGorry, PD | 1 |
| Yung, AR | 1 |
| Desmond, P | 1 |
| Pantelis, C | 1 |
| Blasi, G | 1 |
| Bertolino, A | 1 |
| Brudaglio, F | 1 |
| Sciota, D | 1 |
| Altamura, M | 1 |
| Antonucci, N | 1 |
| Scarabino, T | 1 |
| Weinberger, DR | 1 |
| Nardini, M | 1 |
| Tang, J | 1 |
| Smith, JM | 1 |
| Banerjee, SP | 1 |
| Bhandari, R | 1 |
| Rose, M | 1 |
| Ivey, J | 1 |
| Boyd, C | 1 |
| Coupland, NJ | 1 |
| Ogilvie, CJ | 1 |
| Hegadoren, KM | 1 |
| Seres, P | 1 |
| Hanstock, CC | 1 |
| Allen, PS | 1 |
| Palmio, J | 1 |
| Huuhka, M | 1 |
| Saransaari, P | 1 |
| Oja, SS | 1 |
| Peltola, J | 1 |
| Leinonen, E | 1 |
| Suhonen, J | 1 |
| Keränen, T | 1 |
| Frye, MA | 1 |
| Tsai, GE | 1 |
| Huggins, T | 1 |
| Coyle, JT | 1 |
| Post, RM | 1 |
| Yildiz-Yesiloglu, A | 1 |
| Ankerst, DP | 1 |
| Demirakca, T | 1 |
| Walter, S | 1 |
| Wokrina, T | 1 |
| Sartorius, A | 1 |
| Wildgruber, D | 1 |
| Ajilore, O | 1 |
| Haroon, E | 1 |
| Kumaran, S | 1 |
| Darwin, C | 1 |
| Binesh, N | 1 |
| Mintz, J | 2 |
| Miller, J | 1 |
| Thomas, MA | 1 |
| Kumar, A | 2 |
| Holtzmann, J | 1 |
| Polosan, M | 1 |
| Baro, P | 1 |
| Bougerol, T | 1 |
| Hess, DA | 1 |
| Babb, JS | 1 |
| Klein, RG | 1 |
| Gonen, O | 1 |
| Schuff, N | 1 |
| Neylan, TC | 1 |
| Fox-Bosetti, S | 1 |
| Lenoci, M | 1 |
| Samuelson, KW | 1 |
| Studholme, C | 1 |
| Kornak, J | 1 |
| Marmar, CR | 1 |
| Weiner, MW | 1 |
| Maes, M | 1 |
| Verkerk, R | 1 |
| Vandoolaeghe, E | 1 |
| Lin, A | 1 |
| Scharpé, S | 1 |
| Auer, DP | 1 |
| Pütz, B | 1 |
| Kraft, E | 1 |
| Lipinski, B | 1 |
| Schill, J | 1 |
| Murata, T | 1 |
| Kimura, H | 1 |
| Omori, M | 1 |
| Kado, H | 1 |
| Kosaka, H | 1 |
| Iidaka, T | 1 |
| Itoh, H | 1 |
| Wada, Y | 1 |
| Kusumakar, V | 1 |
| Gates, L | 1 |
| Sparkes, SJ | 1 |
| Khan, SC | 1 |
| Thomas, A | 1 |
| Lavretsky, H | 1 |
| Yue, K | 1 |
| Huda, A | 1 |
| Curran, J | 1 |
| Venkatraman, T | 1 |
| Estanol, L | 1 |
| Mega, M | 1 |
| Toga, A | 1 |
| Grachev, ID | 1 |
| Thomas, PS | 1 |
| Ramachandran, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Duloxetine for Chronic Depression: a Double-blind Study[NCT00360724] | Phase 4 | 65 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Efficacy and Safety of Augmentation of Creatine for the Patients With Major Depressive Disorder[NCT00729755] | 59 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Ketamine Frequency Treatment for Major Depressive Disorder[NCT00646087] | Phase 4 | 0 participants (Actual) | Interventional | 2008-03-31 | Withdrawn (stopped due to Pilot study determined that this study would not be feasible.) | ||
| An Investigation of the Antidepressant Efficacy of Memantine, an NMDA Antagonist With Neurotrophic Properties in Major Depression[NCT00040261] | Phase 3 | 112 participants | Interventional | 2002-06-30 | Completed | ||
| An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression[NCT00054704] | Phase 2 | 19 participants (Actual) | Interventional | 2003-02-28 | Terminated (stopped due to Placebo was better than active drug.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.~When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]~0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.~Higher total scores indicate more severe depressive symptoms." (NCT00360724)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 12.7 |
| Placebo Treatment | 15.5 |
"Beck Depression Inventory (BDI)is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression.~When the test is scored, a value of 0 to 3 is assigned for each answer and then the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:[7]~0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression.~Higher total scores indicate more severe depressive symptoms." (NCT00360724)
Timeframe: Week 10
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 8.5 |
| Placebo Treatment | 10.1 |
"The Clinical Global Impression - Improvement(CGI-I) is a 7-point scale that rate patient's total improvement whether or not comparing to his/her condition at baseline.~0 = Not assessed~= Very much improved~= Much improved~= Minimally improved~= No change~= Minimally worse~= Much worse~= Very much worse Higher score=greatest worsening" (NCT00360724)
Timeframe: 10 weeks
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 2.4 |
| Placebo Treatment | 3 |
"CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).~Scores from 0 to 82 with higher score indicating worse depression" (NCT00360724)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 36.9 |
| Placebo Treatment | 37.4 |
"CDRS is a 20-item clinician-rated inventory for chronic depressive symptoms. Each item was characterized by an explanatory or illustrative description and rated from 0 (symptom absent) to 4 (severe symptoms).~Scores from 0 to 82 with higher score indicating worse depression" (NCT00360724)
Timeframe: Week 10
| Intervention | scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 19.1 |
| Placebo Treatment | 28.5 |
"A commonly used rating scale for global social function.~Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).~61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others~1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.~0 Inadequate information" (NCT00360724)
Timeframe: Baseline
| Intervention | points on rating scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 62.6 |
| Placebo Treatment | 58.3 |
"A commonly used rating scale for global social function.~Range from 0 to 100; higher score=better functioning. 91 - 100 No symptoms. 81 - 90 Absent or minimal symptoms 71 - 80 no more than slight impairment in social, occupational, or school functioning (e.g., temporarily falling behind in schoolwork).~61 - 70 Some mild symptoms 51 - 60 Moderate symptoms 41 - 50 Serious symptoms 31 - 40 Some impairment in reality testing or communication 21 - 30 Behavior is considerably influenced by delusions or hallucinations or serious impairment, in communication or judgment 11 - 20 Some danger of hurting self or others~1 - 10 Persistent danger of severely hurting self or others or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death.~0 Inadequate information" (NCT00360724)
Timeframe: Week 10
| Intervention | points on rating scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 69.9 |
| Placebo Treatment | 65.7 |
HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression (NCT00360724)
Timeframe: Baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 14.1 |
| Placebo Treatment | 14.9 |
HDRS-24 total score, standardly used rating scale for depression. Score 0-7 no depression; Score 8-16 mild depression; Score 17-23 moderate depression; Score 24 and up severe depression. Range= 0 to 75, higher score=worse depression (NCT00360724)
Timeframe: Week 10
| Intervention | Scores on a scale (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 5 |
| Placebo Treatment | 10 |
To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density. (NCT00360724)
Timeframe: Baseline
| Intervention | percentage of connecting nods (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 0.21 |
| Placebo Treatment | 0.24 |
To use resting-state fMRI to study the effects of antidepressant therapy on default mode network (DMN) connectivity density. (NCT00360724)
Timeframe: Follow up
| Intervention | percentage of connecting nods (Mean) |
|---|---|
| Duloxetine (Cymbalta) | 0.16 |
| Placebo Treatment | 0.19 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated assessment of depression symptoms. Patients were rated weekly on 10 symptoms on a scale of 0 to 6 for each item, where 0 indicated no symptoms and 6 indicated the highest severity of that symptom. Total scores range from 0 to 60, where a moderate severity of depression would be present with a score of at least 20. (NCT00054704)
Timeframe: 8 weeks
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Riluzole | 29.551 |
| Placebo | 23.723 |
7 reviews available for aspartic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
Glutamatergic and N-Acetylaspartate Metabolites in Bipolar Disorder: A Systematic Review and Meta-Analysis of Proton Magnetic Resonance Spectroscopy Studies.
Topics: Aspartic Acid; Bipolar Disorder; Depressive Disorder, Major; Glutamic Acid; Glutamine; Humans; Proto | 2022 |
Brain metabolic derangements examined using
Topics: Animals; Aspartic Acid; Brain; Depression; Depressive Disorder, Major; Glutamic Acid; Glutamine; Pro | 2023 |
Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Depression; Depressive Disorder, Major; Female; Glutamic Aci | 2019 |
Neurobiology of generalized anxiety disorder.
Topics: Anxiety Disorders; Aspartic Acid; Brain; Cognition; Comorbidity; Creatine; Depressive Disorder, Majo | 2009 |
Glutamate and depression: clinical and preclinical studies.
Topics: Animals; Antidepressive Agents; Aspartic Acid; Calcium; Clinical Trials as Topic; Depressive Disorde | 2003 |
Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis.
Topics: Aspartic Acid; Brain; Choline; Creatine; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutam | 2006 |
[ECT: from neuronal plasticity to mechanisms underlying antidepressant medication effect].
Topics: Antidepressive Agents; Aspartic Acid; Brain; Brain-Derived Neurotrophic Factor; Choline; Depressive | 2007 |
8 trials available for aspartic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
Effects of the antidepressant medication duloxetine on brain metabolites in persistent depressive disorder: A randomized, controlled trial.
Topics: Adult; Antidepressive Agents; Aspartic Acid; Brain; Depressive Disorder, Major; Double-Blind Method; | 2019 |
Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Cerebellum; Choline; Depressive Disorder, M | 2014 |
Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder.
Topics: Adult; Aged; Aspartic Acid; Brain; Case-Control Studies; Citalopram; Creatine; Depressive Disorder, | 2016 |
Early increase in marker of neuronal integrity with antidepressant treatment of major depression: 1H-magnetic resonance spectroscopy of N-acetyl-aspartate.
Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Biomarkers; Citalopram; Depressive Disorder | 2012 |
Glutamate normalization with ECT treatment response in major depression.
Topics: Adult; Aspartic Acid; Case-Control Studies; Choline; Depressive Disorder, Major; Electroconvulsive T | 2013 |
Hippocampal N-acetylaspartate and morning cortisol levels in drug-naive, first-episode patients with major depressive disorder: effects of treatment.
Topics: Adolescent; Adult; Antidepressive Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; De | 2012 |
Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo.
Topics: Acetylcysteine; Aspartic Acid; Depressive Disorder, Major; Double-Blind Method; Female; Free Radical | 2013 |
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine; | 1998 |
62 other studies available for aspartic acid and Depressive Disorder, Major
| Article | Year |
|---|---|
Correlations between facial emotion processing and biochemical abnormalities in untreated adolescent patients with major depressive disorder: A proton magnetic resonance spectroscopy study.
Topics: Adolescent; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Emotions; Humans; Prefront | 2022 |
Associations between executive function impairment and biochemical abnormalities in depressed adolescents with non-suicidal self-injury.
Topics: Adolescent; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Executive Function; Humans | 2022 |
Childhood trauma history is linked to abnormal brain metabolism of non-medicated adult patients with major depressive disorder.
Topics: Adult; Adverse Childhood Experiences; Aspartic Acid; Brain; Child, Preschool; Choline; Creatine; Cro | 2022 |
Regional metabolic heterogeneity in anterior cingulate cortex in major depressive disorder: A multi-voxel
Topics: Aspartic Acid; Depressive Disorder, Major; Glutamic Acid; Glutamine; Gyrus Cinguli; Humans; Inositol | 2022 |
Cognitive dysfunction and neurometabolic alternations in major depressive disorder with gastrointestinal symptoms.
Topics: Aspartic Acid; Choline; Cognitive Dysfunction; Creatine; Depressive Disorder, Major; Humans; Proton | 2023 |
The Utility of Amino Acid Metabolites in the Diagnosis of Major Depressive Disorder and Correlations with Depression Severity.
Topics: Amino Acids; Aspartic Acid; Biomarkers; Depression; Depressive Disorder, Major; Glutamic Acid; Glyci | 2023 |
Plasma Neuronal and Glial Markers and Anterior Cingulate Metabolite Levels in Major Depressive Disorder: A Pilot Study.
Topics: Adult; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Female; Gyrus Cinguli; Humans; | 2020 |
Altered neurometabolism in major depressive disorder: A whole brain
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Depressive Disorder, Major; Energy Metabolism; Femal | 2020 |
Neurotransmitters and Neurometabolites in Late-Life Depression: A Preliminary Magnetic Resonance Spectroscopy Study at 7T.
Topics: Aspartic Acid; Creatine; Depression; Depressive Disorder, Major; Glutamic Acid; Gyrus Cinguli; Human | 2021 |
A pilot study of cortical glutathione in youth with depression.
Topics: Adolescent; Anhedonia; Aspartic Acid; Case-Control Studies; Child; Choline; Creatine; Depression; De | 2017 |
Correlations between working memory impairment and neurometabolites of prefrontal cortex and lenticular nucleus in patients with major depressive disorder.
Topics: Adult; Aspartic Acid; Case-Control Studies; Choline; Corpus Striatum; Creatine; Depressive Disorder, | 2018 |
Magnetic resonance (MR) spectroscopic measurement of γ-aminobutyric acid (GABA) in major depression before and after electroconvulsive therapy.
Topics: Adult; Aspartic Acid; Depressive Disorder, Major; Electroconvulsive Therapy; Female; gamma-Aminobuty | 2019 |
Hippocampal abnormalities of glutamate/glutamine, N-acetylaspartate and choline in patients with depression are related to past illness burden.
Topics: Adult; Aspartic Acid; Case-Control Studies; Choline; Cost of Illness; Cross-Sectional Studies; Depre | 2013 |
Progressive decrease of N-acetylaspartate to total creatine ratio in the pregenual anterior cingulate cortex in patients with major depressive disorder: longitudinal 1H-MR spectroscopy study.
Topics: Adult; Antidepressive Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; Cross-Sectiona | 2014 |
Decreased plasma neuroactive amino acids and increased nitric oxide levels in melancholic major depressive disorder.
Topics: Adult; Aged; Amino Acids; Antidepressive Agents; Aspartic Acid; Biomarkers; Depressive Disorder, Maj | 2014 |
Amino acid metabolic dysfunction revealed in the prefrontal cortex of a rat model of depression.
Topics: Amino Acids; Animals; Aspartic Acid; Behavior, Animal; beta-Alanine; Depressive Disorder, Major; Dis | 2015 |
Similarities of biochemical abnormalities between major depressive disorder and bipolar depression: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Brain; Choline; Creatine; Depressive Disorder, M | 2014 |
The correlation between biochemical abnormalities in frontal white matter, hippocampus and serum thyroid hormone levels in first-episode patients with major depressive disorder.
Topics: Adult; Aspartic Acid; Brain Chemistry; Choline; Creatine; Depressive Disorder, Major; Female; Hippoc | 2015 |
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress | 2015 |
Increased ventricular cerebrospinal fluid lactate in depressed adolescents.
Topics: Adolescent; Aspartic Acid; Cerebral Ventricles; Cerebrospinal Fluid; Choline; Creatine; Depressive D | 2016 |
Evaluating metabolites in patients with major depressive disorder who received mindfulness-based cognitive therapy and healthy controls using short echo MRSI at 7 Tesla.
Topics: Adult; Aspartic Acid; Case-Control Studies; Caudate Nucleus; Cerebral Cortex; Cognitive Behavioral T | 2016 |
Increased pregenual anterior cingulate glucose and lactate concentrations in major depressive disorder.
Topics: Adult; Aspartic Acid; Brain; Depressive Disorder, Major; Energy Metabolism; Female; Glucose; Gyrus C | 2017 |
Prefrontal inositol levels and implicit decision-making in healthy individuals and depressed patients.
Topics: Adult; Aspartic Acid; Decision Making; Delay Discounting; Depressive Disorder, Major; Diagnostic and | 2016 |
A pilot study of hippocampal N-acetyl-aspartate in youth with treatment resistant major depression.
Topics: Adolescent; Aspartic Acid; Brain; Case-Control Studies; Depressive Disorder, Major; Depressive Disor | 2017 |
Main Effects of Diagnoses, Brain Regions, and their Interaction Effects for Cerebral Metabolites in Bipolar and Unipolar Depressive Disorders.
Topics: Adult; Aspartic Acid; Biomarkers; Bipolar Disorder; Case-Control Studies; Choline; Creatine; Depress | 2016 |
Medial temporal N-acetyl-aspartate in pediatric major depression.
Topics: Adolescent; Aspartic Acid; Child; Choline; Creatine; Depressive Disorder, Major; Female; Humans; Mal | 2008 |
Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response.
Topics: Adult; Aspartic Acid; Case-Control Studies; Choline; Depressive Disorder, Major; Female; gamma-Amino | 2009 |
Biochemical abnormalities of the medial temporal lobe and medial prefrontal cortex in late-life depression.
Topics: Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Energy Metabolism; Functional Laterali | 2009 |
Proton magnetic resonance spectroscopy of late-life major depressive disorder.
Topics: Aged; Aging; Aspartic Acid; Basal Ganglia; Biomarkers; Brain; Choline; Cognition; Creatine; Depressi | 2009 |
Hippocampal metabolic abnormalities at first onset and with recurrent episodes of a major depressive disorder: a proton magnetic resonance spectroscopy study.
Topics: Adult; Analysis of Variance; Aspartic Acid; Choline; Depressive Disorder, Major; Female; Glutamic Ac | 2009 |
The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression.
Topics: Adult; Arousal; Aspartic Acid; Blood Glucose; Corpus Callosum; Depressive Disorder, Major; Dominance | 2009 |
Antidepressant effect detected on proton magnetic resonance spectroscopy in drug-naïve female patients with first-episode major depression.
Topics: Adult; Antidepressive Agents; Aspartic Acid; Case-Control Studies; Choline; Creatine; Depressive Dis | 2009 |
Normal metabolite levels in the left dorsolateral prefrontal cortex of unmedicated major depressive disorder patients: a single voxel (1)H spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Brain Mapping; Case-Control Studies; Chi-Square Distribution; Crea | 2009 |
Neuroanatomical correlates of depression in post traumatic brain injury: preliminary results of a pilot study.
Topics: Adult; Aspartic Acid; Basal Ganglia; Brain; Brain Injuries; Case-Control Studies; Choline; Cognition | 2010 |
Brain proton magnetic resonance spectroscopic study of insight among elders with late-life depression in remission.
Topics: Aged; Aspartic Acid; Awareness; Choline; Creatine; Depressive Disorder, Major; Dominance, Cerebral; | 2010 |
Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Depressive Disorder, Major; Dipeptides; Female; Human | 2011 |
Reduced medial prefrontal N-acetyl-aspartate levels in pediatric major depressive disorder: a multi-voxel in vivo(1)H spectroscopy study.
Topics: Adolescent; Affect; Aspartic Acid; Brain Mapping; Child; Creatine; Depressive Disorder, Major; Femal | 2010 |
Ventromedial prefrontal spectroscopic abnormalities over the course of depression: a comparison among first episode, remitted recurrent and chronic patients.
Topics: Adult; Age of Onset; Aspartic Acid; Choline; Chronic Disease; Depressive Disorder, Major; Disease Pr | 2011 |
Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy.
Topics: Adult; Analysis of Variance; Aspartic Acid; Creatine; Depressive Disorder, Major; Electroconvulsive | 2011 |
The neuronal transporter gene SLC6A15 confers risk to major depression.
Topics: Adult; Amino Acid Transport Systems, Neutral; Analysis of Variance; Animals; Aspartic Acid; Chromoso | 2011 |
Frontal white matter biochemical abnormalities in first-episode, treatment-naive patients with major depressive disorder: a proton magnetic resonance spectroscopy study.
Topics: Adolescent; Adult; Aspartic Acid; Brain Chemistry; Brain Diseases; Choline; Creatine; Depressive Dis | 2012 |
Increased stress reactivity is associated with reduced hippocampal activity and neuronal integrity along with changes in energy metabolism.
Topics: Animals; Aspartic Acid; Behavior, Animal; Cognition Disorders; Depressive Disorder, Major; Disease M | 2012 |
[Alterations of plasma aspartic acid, glycine and asparagine levels in patients with major depressive disorder].
Topics: Adult; Aged; Antidepressive Agents; Asparagine; Aspartic Acid; Depressive Disorder, Major; Female; G | 2012 |
Age-modulated association between prefrontal NAA and the BDNF gene.
Topics: Adolescent; Adult; Aging; Aspartic Acid; Brain-Derived Neurotrophic Factor; Depression; Depressive D | 2013 |
Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression.
Topics: Adult; Aged; Amygdala; Aspartic Acid; Depressive Disorder, Major; Electroconvulsive Therapy; Female; | 2003 |
Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy.
Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Depressive Disorder, Major; Electroconvulsive | 2003 |
Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study.
Topics: Adult; Aspartic Acid; Brain; Brain Chemistry; Brain Mapping; Choline; Creatine; Depressive Disorder, | 2003 |
Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Brain Mapping; Choline; Creatine; Depressive Dis | 2003 |
Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Cerebral Cortex; Choline; Creatine; Depressive D | 2004 |
Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls.
Topics: Adolescent; Aspartic Acid; Child; Choline; Creatine; Depressive Disorder, Major; Female; Glutamic Ac | 2004 |
Decreased prefrontal Myo-inositol in major depressive disorder.
Topics: Adult; Aspartic Acid; Brain Chemistry; Brain Mapping; Case-Control Studies; Choline; Creatine; Depre | 2005 |
Changes in plasma amino acids after electroconvulsive therapy of depressed patients.
Topics: Adult; Aged; Aspartic Acid; Depressive Disorder, Major; Electroconvulsive Therapy; Electroencephalog | 2005 |
Low cerebrospinal fluid glutamate and glycine in refractory affective disorder.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Aspartic Acid; Bipolar Disorder; Ch | 2007 |
Subcortical and medial temporal MR-detectable metabolite abnormalities in unipolar major depression.
Topics: Adult; Aspartic Acid; Brain Chemistry; Cell Membrane; Cerebral Cortex; Creatine; Depressive Disorder | 2007 |
Measurement of brain metabolites in patients with type 2 diabetes and major depression using proton magnetic resonance spectroscopy.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Brain Chemistry; Choline; Creatine; Depressive Disord | 2007 |
Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study.
Topics: Adolescent; Aspartic Acid; Caudate Nucleus; Choline; Cohort Studies; Creatine; Depressive Disorder, | 2007 |
Abnormal N-acetylaspartate in hippocampus and anterior cingulate in posttraumatic stress disorder.
Topics: Adult; Alcoholism; Algorithms; Aspartic Acid; Atrophy; Combat Disorders; Comorbidity; Conditioning, | 2008 |
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Female; Frontal Lobe; Glu | 2000 |
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Female; Frontal Lobe; Glu | 2000 |
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Female; Frontal Lobe; Glu | 2000 |
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Female; Frontal Lobe; Glu | 2000 |
MRI white matter hyperintensities, (1)H-MR spectroscopy and cognitive function in geriatric depression: a comparison of early- and late-onset cases.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Depressive Disorder, Major; Energy | 2001 |
Left medial temporal cytosolic choline in early onset depression.
Topics: Adolescent; Amygdala; Aspartic Acid; Choline; Creatine; Cytosol; Depressive Disorder, Major; Dominan | 2001 |
Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy.
Topics: Aged; Aspartic Acid; Choline; Creatine; Depressive Disorder, Major; Dominance, Cerebral; Energy Meta | 2002 |
Decreased levels of N-acetylaspartate in dorsolateral prefrontal cortex in a case of intractable severe sympathetically mediated chronic pain (complex regional pain syndrome, type I).
Topics: Adult; Anxiety Disorders; Aspartic Acid; Chronic Disease; Depressive Disorder, Major; Female; Humans | 2002 |